（图片来源：摄图网） 12月17日，西安市人民政府办公厅印发《促进生物医药产业能力提升实施方案(2025—2027年)》，提出到 2027年，全市生物医药产业规模达到400亿元，其中中药、化药生物药、医疗器械、消费医疗产业链群分别 达到90亿元、120亿元、60亿元、130亿元。规模以上企业突破130户，培育年产值超80亿元、30亿元、20亿 元、10亿元以上企业1户、1户、2户、4户，推动2户企业上市。 生物医药产业关乎国计民生与国家安全，是最具成长性、最能体现国家科技竞争力的支柱产业之一，前景广 阔。前瞻产业研究院预计到2029年，中国医药制造规上企业营业收入将达到5.4万亿元，2024-2029年年均增 长率达到14.04%。 西安生物医药产业历经近90年积淀，已成为西北地区最重要的研发制造基地。2022年，全市生物医药规上产 值达290亿元，形成了以高新区、经开区、航天基地、西咸新区为核心载体的产业布局。 作为产业核心集聚区，西安高新区截至2022年底集聚生物医药相关企业4120家、上市企业9家，产业规模突 破600亿元，位居中西部国家高新区前列。当前产业已构建起以化学药、生物药、中成药、医疗器械为基 ...

Core Insights - The Shanghai biopharmaceutical industry is experiencing significant growth, projected to reach a scale of 1 trillion yuan by 2024, with a compound annual growth rate of 8.94% from 2021 to 2024 [2] - The industry is recognized as a strategic emerging sector, receiving national attention and support, with plans to allocate more resources and policy backing during the 14th Five-Year Plan [2][10] - Shanghai is establishing itself as a global hub for biopharmaceutical innovation, with a focus on high-end, intelligent, and international development [8][10] Industry Growth and Scale - The biopharmaceutical industry in Shanghai grew from 761.71 billion yuan in 2021 to an expected 984.70 billion yuan in 2024, with the first half of 2025 projected at 500.57 billion yuan [2] - China's biopharmaceutical market reached 2.95 trillion yuan in 2023, leading globally in chemical raw material drug exports, drug formulation capacity, and vaccine supply [2] Regional Cluster Advantages - Shanghai, Guangdong, and Beijing exhibit significant advantages in biopharmaceutical industry clusters, with Shanghai hosting 19 of the top 20 global pharmaceutical giants [3] - The local ecosystem includes innovative companies such as Fosun Pharma and Junshi Biosciences, fostering resource sharing and collaborative innovation [3] Innovation and Research - During the 13th Five-Year Plan, Shanghai achieved breakthroughs in synthetic biology, stem cell research, and neuroscience, supported by 17 national key laboratories [7] - The number of patent applications in the biopharmaceutical sector in Shanghai has been rapidly increasing, surpassing 8,000 in 2020 [7] Policy and Investment Support - The Shanghai government has established a 22.5 billion yuan biopharmaceutical industry mother fund, with a leverage ratio of 5.59 times [10] - The city aims to enhance its policy framework for the entire biopharmaceutical innovation chain and promote global collaboration [10] Future Outlook - The biopharmaceutical industry is set to become a new economic pillar for Shanghai, alongside artificial intelligence and integrated circuits, creating a core framework for future industrial development [10]